RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells.
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
GSC 富集的鞘糖脂对 iNKT 细胞功能的调节可能促进 GBM 的免疫抑制,并突显硫苷脂生成作为 GBM 治疗潜在靶点的重要性。
为开发有效的胶质母细胞瘤(GBM)疗法,需要更深入地了解其潜在的免疫调节机制。恒定自然杀伤T(iNKT)细胞是一种非常规T细胞,能够识别脂质抗原,并已知在其他癌症类型中调节肿瘤免疫。鉴于大脑富含脂质以及GBM细胞独特的代谢活性,我们假设GBM富集的脂质能够引导iNKT细胞促成该疾病的免疫抑制特性。
采用液相色谱-质谱联用技术测定了多种人GBM干细胞样细胞(GSC)系、低级别胶质瘤细胞系及正常人星形胶质细胞的脂质水平。在iNKT刺激实验中,使用人iNKT细胞系或来自健康供者和GBM患者的PBMC样本,对GBM干细胞样细胞富集的脂质进行测试,以确定其抗原性并表征iNKT激活的性质。
多种脂质种类被发现独特地富集于GSCs中。其中许多脂质,称为硫苷脂,当由CD1d呈递时,能以剂量依赖的方式被iNKT细胞识别并激活。对GSCs内硫苷脂合成途径进行药物和基因靶向,导致激活iNKT细胞的能力发生改变。然而,一种脂质——溶血硫苷脂,抑制了iNKT细胞的激活,并抑制了由同源抗原α-半乳糖神经酰胺诱导的激活。
To develop effective therapies for glioblastoma (GBM), a deeper understanding of its underlying immunoregulatory mechanisms is needed. Invariant natural killer T (iNKT) cells are unconventional T cells that recognize lipid antigens and are known to regulate tumor immunity in other cancer types. Given the lipid-rich nature of the brain and the unique metabolic activity of GBM cells, we hypothesized that GBM-enriched lipids could direct iNKT cells to contribute to the immunosuppressive nature of the disease.
Lipid levels of multiple human GBM stem-like cell (GSC) lines, low grade-glioma lines, and normal human astrocytes were determined using liquid-chromatography mass spectrometry. GBM stem-like cell-enriched lipids were tested in iNKT stimulation assays, with either human iNKT cell lines or PBMC samples from both healthy donors and GBM patients, to determine antigenicity and characterize the nature of iNKT activation.
Multiple lipid species were found to be uniquely enriched in GSCs. Many of these lipids, called sulfatides, were recognized by and activated iNKT cells in a dose-dependent manner when presented by CD1d. Pharmaceutical and genetic targeting of the sulfatide synthetic pathway within GSCs resulted in an altered ability to activate iNKT cells. However, one lipid, lyso-sulfatide, inhibited the activation of iNKT cells and suppressed activation induced by a cognate antigen, α-galactosylceramide.
The modulation of iNKT cell functions by GSC-enriched glycosphingolipids may contribute to the immunosuppression of GBM and highlights sulfatide production as a potential therapeutic target for GBM treatment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。